文献速递神经肿瘤

贝伐珠单抗改善复发高级别胶质瘤生存:按医保审批分配治疗的回顾性研究

Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
PubMed 文献 · J Neurooncol · 2020-05-14

德国埃尔朗根放疗科回顾61例复发高级别胶质瘤患者,贝伐珠单抗使用完全由医保报销审批决定:37例(60.7%)获批进入BEV组,24例(39.3%)未获批接受标准治疗。全队列中位总生存7.0个月,BEV组10.3个月优于非BEV组4.2个月(logrank p=0.023),多因素分析HR=0.43(p=0.034)。

要点

  • 医保审批决定的治疗分配下,BEV组中位OS 10.3个月优于非BEV组4.2个月(p=0.023)
  • 二次及以上复发者BEV获益更明显(9.9 vs 2.6个月,p=0.010)
  • 多因素分析BEV对总生存的预后影响仍显著(HR=0.43,p=0.034)

核心结论

  • 结果提示贝伐珠单抗对经多线治疗的复发高级别胶质瘤患者的总生存可能有影响,二次或更晚复发时获益最大。

研究设计与样本

  • 德国埃尔朗根放疗科回顾性研究,2008年6月至2014年1月共61例复发高级别胶质瘤患者,贝伐珠单抗使用由医保报销审批决定,37例(60.7%)获批为BEV组,24例(39.3%)未获批为非BEV组。
  • 生存终点以首次向医保提交BEV申请为参照点定义。

主要发现

  • 全队列中位总生存为7.0个月。
  • BEV组与非BEV组中位OS分别为10.3 vs 4.2个月,logrank p=0.023。
  • 首次复发者BEV vs 非BEV为12.5 vs 10.2个月(p=0.578),二次及以上复发者为9.9 vs 2.6个月(p=0.010)。
  • 多因素分析中贝伐珠单抗对总生存的预后影响仍显著(HR=0.43,p=0.034)。

临床怎么用

  • 对经多线治疗的复发高级别胶质瘤,尤其二次或更晚复发者,可结合医保可及性考虑贝伐珠单抗治疗。
  • 与患者沟通生存获益时需说明证据来自回顾性、按报销审批分配治疗的研究。

局限性

  • 为单中心回顾性研究,样本量61例,治疗分配依赖医保审批而非随机,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite a large number of trials, the role of bevacizumab (BEV) in the treatment of recurrent high-grade gliomas is still controversial. Evidence regarding an effect on overall survival in this context is ultimately inconclusive. At the Department of Radiation Oncology at Erlangen, Germany we treated a large cohort of patients with recurrent gliomas where bevacizumab use was determined exclusively by the health care provider's approval of reimbursement. METHODS: 61 patients (between 06/2008 and 01/2014) with recurrent high-grade gliomas had reimbursement requests for BEV sent to their health insurance. 37 patients out of 61 (60.7%) had their requests approved and therefore received bevacizumab (BEV-arm) as part of their treatment. The remaining 24 (39.3%) patients received standard therapy without bevacizumab (non-BEV-arm). Survival endpoints were defined with reference to the first BEV request to the health insurance provider. RESULTS: Median overall survival (OS) for the whole cohort was 7.0 months. OS was significantly better for BEV vs. Non-BEV patients (median, 10.3 vs. 4.2 months, logrank p = 0.023). There was an increased BEV benefit in cases of higher-order recurrences (first order recurrence BEV vs. Non-BEV, 12.5 vs. 10.2 months, p = 0.578) (second or higher order of recurrence, 9.9 vs. 2.6 months, p = 0.010). On multivariate analysis for overall survival the prognostic impact of bevacizumab (HR = 0.43, p = 0.034) remained significant. CONCLUSION: Our results suggest an influence of BEV on overall survival in a heavily pretreated patient population suffering from high-grade gliomas with BEV benefit being greatest in case of second or later recurrence.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Hofmann S, Schmidt MA, Weissmann T, et al. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider. J Neurooncol. 2020. PMID: 32409944. doi:10.1007/s11060-020-03533-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。